1. American Psychiatric Association. (2022). What is a substance use disorder? Retrieved February 16 from https://www.psychiatry.org/patients-families/addiction/what-is-addiction. Accessed 31 Jan 2022.
2. Bruneau, J., Ahamad, K., Goyer, M. E., Poulin, G., Selby, P., Fischer, B., … Wood, E. (2018). Management of opioid use disorders: A national clinical practice guideline. CMAJ, 190(9), E247–E257. https://doi.org/10.1503/cmaj.170958.
3. Center for Substance Abuse Treatment (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. In Treatment Improvement Protocol (TIP) Series, No. 40.
4. Correctional Service of Canada. (2019). Opioid Agonist Treatment. Retrieved March 23, 2020 from https://www.csc-scc.gc.ca/health/002006-2007-en.shtml.
5. Garcia, C. A., Correa, G. C., Viver, A. D., Kinlock, T. W., Gordon, M. S., Avila, C. A., … Schwartz, R. P. (2007). Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. Journal of Addiction Medicine, 1(3), 126–132. https://doi.org/10.1097/ADM.0b013e31814b8880.